SGLT2 Inhibitors for Coronary Artery Disease Patients

Primary Recommendation Based on Guidelines

• The American College of Cardiology recommends the use of SGLT2 inhibitors, such as empagliflozin, canagliflozin, or dapagliflozin, to reduce major adverse cardiovascular events, cardiovascular death, and heart failure hospitalizations in patients with coronary artery disease, regardless of diabetes status 1
• The American College of Cardiology and American Heart Association guidelines endorse the use of SGLT2 inhibitors with proven cardiovascular benefit as a Class 1 recommendation to reduce the risk of major adverse cardiovascular events in patients with chronic coronary disease and type 2 diabetes 1

Evidence Supporting Use in CAD

Cardiovascular Mortality Benefits

• The European Society of Cardiology guidelines recommend empagliflozin to reduce cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, with a Class 1 recommendation 3

MACE Reduction

• SGLT2 inhibitors reduce non-fatal myocardial infarction by 21 fewer events per 1000 patients, according to the BMJ 5
• SGLT2 inhibitors reduce non-fatal stroke by 21-25 fewer events per 1000 patients across risk strata, according to the BMJ 5

Heart Failure Benefits in CAD Context

• The American College of Cardiology recommends SGLT2 inhibitors as a Class 1 recommendation to reduce cardiovascular death and heart failure hospitalization in CAD patients with heart failure and LVEF ≤40%, regardless of diabetes status 1
• The American College of Cardiology recommends SGLT2 inhibitors as a Class 2a recommendation to decrease heart failure hospitalizations in CAD patients with heart failure and LVEF >40% 1

Implementation Algorithm for CAD Patients

Step 1: Verify Eligibility

• The American Journal of Kidney Diseases recommends an eGFR ≥20 mL/min/1.73 m² for SGLT2 inhibitor use, as levels below this threshold are contraindicated 6
• The American Journal of Kidney Diseases recommends that patients should not have type 1 diabetes for SGLT2 inhibitor use 6
• The Journal of the American College of Cardiology recommends that patients should not have a history of serious hypersensitivity to the drug for SGLT2 inhibitor use 2

Step 2: Select Specific Agent

• The American College of Cardiology recommends that all three agents (empagliflozin, canagliflozin, dapagliflozin) are appropriate for CAD patients, with selection based on individual patient characteristics 1

Step 3: Adjust Concomitant Medications

• The Journal of the American College of Cardiology recommends reducing insulin or sulfonylurea doses by approximately 50% to prevent hypoglycemia when initiating SGLT2 inhibitors 2
• The American Journal of Kidney Diseases recommends considering reducing diuretic doses in patients at risk for volume depletion when initiating SGLT2 inhibitors 6

Step 4: Monitor Initial Response

• The American Journal of Kidney Diseases recommends expecting a reversible eGFR decline of 3-5 mL/min/1.73 m² in the first 4 weeks of SGLT2 inhibitor use, which is hemodynamic and not harmful 6

Critical Safety Considerations

Euglycemic Ketoacidosis Risk

• The American Journal of Kidney Diseases recommends implementing the "STOP DKA" protocol education to prevent euglycemic ketoacidosis in patients taking SGLT2 inhibitors 6

Amputation Risk (Canagliflozin Specific)

• The Journal of the American College of Cardiology recommends exercising caution with canagliflozin in patients with severe peripheral vascular disease, neuropathy, or diabetic foot ulcers due to an increased risk of amputation 2

Bone Fracture Risk (Canagliflozin Specific)

• The Journal of the American College of Cardiology recommends using caution with canagliflozin in patients with osteoporosis due to an increased risk of bone fractures 2

Special Populations

Patients with Reduced LVEF

• The American College of Cardiology recommends SGLT2 inhibitors as mandatory for CAD patients with LVEF ≤40%, unless contraindicated, representing a quality measure per 2024 ACC/AHA guidelines 7

Chronic Kidney Disease

• The European Heart Journal recommends SGLT2 inhibitors to provide kidney protection in CAD patients with CKD, reducing progression of diabetic kidney disease 3
• The American Journal of Kidney Diseases recommends SGLT2 inhibitors as a strong (Class 1) recommendation for CAD patients with CKD and albuminuria ≥200 mg/g, and as a Class 2B recommendation for those with lower albuminuria (UACR <200 mg/g) 6